Sonus, Abbott Laboratories Inc. deal

The companies agreed to develop and distribute EchoGen Emulsion, SNUS's ultrasound contrast agent. Abbott will pay $31 million in up front, clinical support and milestone payments. In addition, Abbott purchased for $4 million warrants to acquire 500,000 shares of SNUS common stock, equal to 6 percent of the company. The warrants are exercisable for five years at $16 per share. SNUS closed Friday at $20.50.

SNUS also will receive 47 percent of net EchoGen revenues in the U.S., a portion of which the company must use to fund its obligations under the agreement. ...